Disparagement: The French Judiciary Supreme Court confirms that using objective differences between originator and generic medecines does not prevent executing a reprehensible strategy and validates the French NCA’s way of taking account of the duration of the practice for the calculation of the amount of the fine (Sanofi/Teva Santé)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On October 18, 2016, the Commercial Chamber of the Court of Cassation issued a decision with ample reasons. about the Plavix® generics smear case. It dismisses in all respects the appeal brought by Sanofi and Sanofi-Aventis against thejudgment of the Court of First Instance of the European Communities in the case of Plavix®. handed down on 18 December 2014 by the Paris Court of Appeal. It will be recalled that, in that judgment, the Paris Court of Appeal dismissed in its entirety the appeal against the decision http://www.autoritedelaconcurrence.... No. 13-D-11 of May 14, 2013, in which the French Competition Authority, after receiving a complaint from Teva